115 related articles for article (PubMed ID: 15699122)
1. Vascular endothelial cells have impaired capacity to present immunodominant, antigenic peptides: a mechanism of cell type-specific immune escape.
Kummer M; Lev A; Reiter Y; Biedermann BC
J Immunol; 2005 Feb; 174(4):1947-53. PubMed ID: 15699122
[TBL] [Abstract][Full Text] [Related]
2. Two preferentially expressed proteins protect vascular endothelial cells from an attack by peptide-specific CTL.
Thommen DS; Schuster H; Keller M; Kapoor S; Weinzierl AO; Chennakesava CS; Wang X; Rohrer L; von Eckardstein A; Stevanovic S; Biedermann BC
J Immunol; 2012 Jun; 188(11):5283-92. PubMed ID: 22544926
[TBL] [Abstract][Full Text] [Related]
3. CTLs directed against HER2 specifically cross-react with HER3 and HER4.
Conrad H; Gebhard K; Krönig H; Neudorfer J; Busch DH; Peschel C; Bernhard H
J Immunol; 2008 Jun; 180(12):8135-45. PubMed ID: 18523278
[TBL] [Abstract][Full Text] [Related]
4. Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro.
Fleischer K; Schmidt B; Kastenmüller W; Busch DH; Drexler I; Sutter G; Heike M; Peschel C; Bernhard H
J Immunol; 2004 Jan; 172(1):162-9. PubMed ID: 14688322
[TBL] [Abstract][Full Text] [Related]
5. The immunodominant, Ld-restricted T cell response to hepatitis B surface antigen (HBsAg) efficiently suppresses T cell priming to multiple Dd-, Kd-, and Kb-restricted HBsAg epitopes.
Schirmbeck R; Stober D; El-Kholy S; Riedl P; Reimann J
J Immunol; 2002 Jun; 168(12):6253-62. PubMed ID: 12055239
[TBL] [Abstract][Full Text] [Related]
6. Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans.
Geluk A; van Meijgaarden KE; Franken KL; Drijfhout JW; D'Souza S; Necker A; Huygen K; Ottenhoff TH
J Immunol; 2000 Dec; 165(11):6463-71. PubMed ID: 11086086
[TBL] [Abstract][Full Text] [Related]
7. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma.
Rimoldi D; Rubio-Godoy V; Dutoit V; Lienard D; Salvi S; Guillaume P; Speiser D; Stockert E; Spagnoli G; Servis C; Cerottini JC; Lejeune F; Romero P; Valmori D
J Immunol; 2000 Dec; 165(12):7253-61. PubMed ID: 11120859
[TBL] [Abstract][Full Text] [Related]
8. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma.
Yamshchikov GV; Mullins DW; Chang CC; Ogino T; Thompson L; Presley J; Galavotti H; Aquila W; Deacon D; Ross W; Patterson JW; Engelhard VH; Ferrone S; Slingluff CL
J Immunol; 2005 Jun; 174(11):6863-71. PubMed ID: 15905528
[TBL] [Abstract][Full Text] [Related]
9. Generation of tumor-reactive CTL against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells.
Meyer zum Büschenfelde C; Nicklisch N; Rose-John S; Peschel C; Bernhard H
J Immunol; 2000 Oct; 165(7):4133-40. PubMed ID: 11034426
[TBL] [Abstract][Full Text] [Related]
10. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.
Valmori D; Gervois N; Rimoldi D; Fonteneau JF; Bonelo A; Liénard D; Rivoltini L; Jotereau F; Cerottini JC; Romero P
J Immunol; 1998 Dec; 161(12):6956-62. PubMed ID: 9862730
[TBL] [Abstract][Full Text] [Related]
11. Antagonism of antiviral and allogeneic activity of a human public CTL clonotype by a single altered peptide ligand: implications for allograft rejection.
Ely LK; Green KJ; Beddoe T; Clements CS; Miles JJ; Bottomley SP; Zernich D; Kjer-Nielsen L; Purcell AW; McCluskey J; Rossjohn J; Burrows SR
J Immunol; 2005 May; 174(9):5593-601. PubMed ID: 15843558
[TBL] [Abstract][Full Text] [Related]
12. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants.
Hoffmann TK; Nakano K; Elder EM; Dworacki G; Finkelstein SD; Appella E; Whiteside TL; DeLeo AB
J Immunol; 2000 Nov; 165(10):5938-44. PubMed ID: 11067956
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.
Jäger E; Chen YT; Drijfhout JW; Karbach J; Ringhoffer M; Jäger D; Arand M; Wada H; Noguchi Y; Stockert E; Old LJ; Knuth A
J Exp Med; 1998 Jan; 187(2):265-70. PubMed ID: 9432985
[TBL] [Abstract][Full Text] [Related]
14. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity.
Keogh E; Fikes J; Southwood S; Celis E; Chesnut R; Sette A
J Immunol; 2001 Jul; 167(2):787-96. PubMed ID: 11441084
[TBL] [Abstract][Full Text] [Related]
15. Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues.
Vertuani S; Sette A; Sidney J; Southwood S; Fikes J; Keogh E; Lindencrona JA; Ishioka G; Levitskaya J; Kiessling R
J Immunol; 2004 Mar; 172(6):3501-8. PubMed ID: 15004150
[TBL] [Abstract][Full Text] [Related]
16. Solid-phase epitope recovery: a high throughput method for antigen identification and epitope optimization.
Lawendowski CA; Giurleo GM; Huang YY; Franklin GJ; Kaplan JM; Roberts BL; Nicolette CA
J Immunol; 2002 Sep; 169(5):2414-21. PubMed ID: 12193709
[TBL] [Abstract][Full Text] [Related]
17. In vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones.
Schreurs MW; Scholten KB; Kueter EW; Ruizendaal JJ; Meijer CJ; Hooijberg E
J Immunol; 2003 Sep; 171(6):2912-21. PubMed ID: 12960314
[TBL] [Abstract][Full Text] [Related]
18. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
Valmori D; Fonteneau JF; Lizana CM; Gervois N; Liénard D; Rimoldi D; Jongeneel V; Jotereau F; Cerottini JC; Romero P
J Immunol; 1998 Feb; 160(4):1750-8. PubMed ID: 9469433
[TBL] [Abstract][Full Text] [Related]
19. Modulation of HLA-A*0201-restricted T cell responses by natural polymorphism in the IE1(315-324) epitope of human cytomegalovirus.
Prod'homme V; Retière C; Imbert-Marcille BM; Bonneville M; Hallet MM
J Immunol; 2003 Feb; 170(4):2030-6. PubMed ID: 12574373
[TBL] [Abstract][Full Text] [Related]
20. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.
Chen JL; Dunbar PR; Gileadi U; Jäger E; Gnjatic S; Nagata Y; Stockert E; Panicali DL; Chen YT; Knuth A; Old LJ; Cerundolo V
J Immunol; 2000 Jul; 165(2):948-55. PubMed ID: 10878370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]